PREVOX: Long Term Effect of Oxaliplatin Treatment in Cancer Survivors
Study Details
Study Description
Brief Summary
This project will evaluate the neurotoxic effects of oxaliplatin. Oxaliplatin is considered the most neurotoxic chemotherapy, and at the origin of peripheral neuropathies. These neuropathies remain a problem in oncology because currently no prevention strategy has proved effective and only duloxetine seems to have a therapeutic benefit in improving symptoms. In the case of oxaliplatin, neuropathy forced oncologists to reduce the dose or to stop the chemotherapy, potentially degrading the oncological prognosis.
Objective of this study will be to assess, on a large number of patients (n> 500) who completed adjuvant chemotherapy (FOLFOX), the intensity of neuropathic disorders out of 5 years after the end of chemotherapy. Furthermore, this study should enable an assessment of the relationship between the intensity of neuropathy and comorbidities, such as anxiety and depression and health related quality of life of patients.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
Detailed Description
Oxaliplatin remains the reference treatment of advanced colorectal cancer and more broadly of digestive cancers, incorporated in the FOLFOX protocol (folinic acid, 5-Fu, Oxaliplatin). But oxaliplatin chemotherapy is certainly the most neurotoxic, as on average 90% of patients develop acute neuropathic disorders (within hours or days of the infusion) and 30% to 50% of patients develop a chronic neuropathy with repeated cycles of chemotherapy. The neuropathic grade and duration of symptoms remain variable across studies. Although symptoms improve with time, long-term studies suggest a persistent neuropathy beyond 24 months. Moreover, Vatandoust and colleagues suggest that chemotherapy-induced neuropathy is more frequent and severe over the long term (≥ 12 months) than in previous works published.
In cancer survivors, neuropathy induced by oxaliplatin has a deleterious impact on their quality of life. But, few studies are available on the consequences of oxaliplatin-induced neuropathy in these patients, while these patients remain, in 2003, the third largest group of cancer survivors.
Only 7 studies have specifically evaluated neuropathic disorders induced by oxaliplatin after chemotherapy. Moreover, as pointed Vatandoust and colleagues, there is a real need to understand the long term effects of this chemotherapy-induced neuropathy. More specifically, only two studies have evaluated the effects of neuropathy on quality of life and comorbidities of patients.
Objective of this study will be to assess, on a large number of patients (n> 500) who completed adjuvant chemotherapy (FOLFOX), the intensity of neuropathic disorders out of 5 years after the end of chemotherapy. Furthermore, this study should enable an assessment of the relationship between the intensity of neuropathy and comorbidities, such as anxiety and depression and health related quality of life of patients.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| colorectal cancer survivors
|
Drug: Oxaliplatin
Intensity of neuropathy induced by oxaliplatin evaluated by the QLQ-CIPN20 Questionnaire (EORTC).
|
Outcome Measures
Primary Outcome Measures
- Intensity of neuropathy induced by oxaliplatin evaluated by the QLQ-CIPN20 Questionnaire (EORTC). [once and until 5 years after the end of chemotherapy]
Secondary Outcome Measures
- Thermal hypersensitivity to cold and hot assessed by VAS. [once and until 5 years after the end of chemotherapy]
- Neuropathic pain evaluated by the DN4 interview questionnaire. [once and until 5 years after the end of chemotherapy]
- Anxiety and depression assessed by HADS questionnaire. [once and until 5 years after the end of chemotherapy]
- Health related quality of life assessed by QLQ-C30 questionnaire (EORTC). [once and until 5 years after the end of chemotherapy]
- Grade of neuropathy during chemotherapy (NCI-CTCAE). [once and until 5 years after the end of chemotherapy]
- Cumulative dose (mg / m²) and dose intensity (mg / m² / week) of oxaliplatin [once and until 5 years after the end of chemotherapy]
- pain assessed by visual analog scale (VAS). [once and until 5 years after the end of chemotherapy]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
• Living patient who received adjuvant chemotherapy (FOLFOX).
-
Patient in remission.
-
FOLFOX chemotherapy over for 0-5 years.
-
Oral Non-opposition to participation in the study
Exclusion Criteria:
-
• Patient unable to understand or respond to questionnaires.
-
Age <18 years.
-
Neurological diseases (eg Parkinson's disease, stroke, fibromyalgia ...).
-
Legal incapacity (person deprived of liberty or under guardianship).
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | CHU Clermont-Ferrand | Clermont-Ferrand | France | 63003 |
Sponsors and Collaborators
- University Hospital, Clermont-Ferrand
Investigators
- Principal Investigator: Denis PEZET, University Hospital, Clermont-Ferrand
Study Documents (Full-Text)
None provided.More Information
Publications
- CHU-0290